The risk of Type 2 diabetes is 14% lower for every 100 mg increase in magnesium intake per day in people with a body mass index over 25 (overweight or obese) according to a study from China.

“This meta-analysis provides further evidence supporting that magnesium intake is significantly inversely associated with risk of type 2 diabetes in a dose-response manner,” the authors of the study concluded.

Intensive glucose-lowering treatment does NOT lower the risk of death in Type 2 diabetics according to a meta-analysis of 13 studies.

The total risk of death was 4% HIGHER in those given intensive glucose-lowering treatment compared to those who were not given these treatments, however, the difference was not statistically significant, meaning this difference may be due to random chance.

Intensive glucose-lowering treatment was found to INCREASE the risk a congestive heart failure by 47% in Type 2 diabetics according to a meta-analysis of 13 studies.

The diabetes drug metformin (Glucophage) reduced the risk of death by 36% over 10.7 years in Type 2 diabetics according to a 1998 study.

Metformin ALONE was the ONLY diabetes drug to reduce the risk of death.

Adding the diabetes drug metformin (Glucophage) to Type 2 diabetics who were already taking a sulphonylurea DOUBLED the risk of diabetes-related death—a 96% increase—over 10.7 years compared with continued sulphonylurea alone according to a 1998 study.

Metformin ALONE was the ONLY diabetes drug to reduce the risk of death.

Diabetes, defined as having a blood sugar level of 140 mg/dl or greater, increased the risk of dying 2.1-fold during the next eight years in patients with coronary artery disease (CAD) compared to those with normal blood sugar levels of 80-109 mg/dl according to a 2004 study.

Diabetes, defined as having a blood sugar level of 140 mg/dl or greater, increased the risk of dying from coronary artery disease (CAD) 2.3-fold during the next eight years in patients with coronary artery disease (CAD) compared to those with normal blood sugar levels of 80-109 mg/dl according to a 2004 study.

Borderline diabetes, defined as having a blood sugar level of 126-139 mg/dl, increased the risk of dying from coronary artery disease (CAD) 1.7-fold during the next eight years in patients with coronary artery disease (CAD) compared to those with normal blood sugar levels of 80-109 mg/dl according to a 2004 study.

A high intake of vegetable protein and fat was associated with a 22% lower risk of Type 2 diabetes in men during a 20 year follow-up when comparing the top 20% of people with the lowest 20% of people according to a study from researchers at the Harvard School of Public Health in Boston, Massachusetts, USA.

A high intake of animal protein and fat was associated with a 37% greater risk of Type 2 diabetes in men during a 20 year follow-up when comparing the top 20% of people with the lowest 20% of people according to a study from researchers at the Harvard School of Public Health in Boston, Massachusetts, USA.

The antidepressant Zoloft (sertraline) increases the risk of diabetes 25%—or 1.3-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The dose was 50 mg per day or above that increased the risk.

The antidepressant Paxil (paroxetine) increases the risk of diabetes 33%—or 1.3-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The dose was 20 mg per day or above that increased the risk.

The antidepressant Elavil (amitriptyline) increases the risk of diabetes 43% according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The dose was 38 mg per day or above that increased the risk.

The antidepressant Paxil (paroxetine) increases the risk of diabetes 103%—or 2-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The antidepressant Desyrel or Oleptro (trazodone) increases the risk of diabetes 116%—or 2.2-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The antidepressant nortriptyline (Aventyl HCl or Pamelor) increases the risk of diabetes 122%—or 2.2-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The dose was 30 mg per day or above that increased the risk.

The antidepressant Anafranil (clomipramine) increases the risk of diabetes 123%—or 2.2-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The dose was 20 mg per day or above that increased the risk.

The antidepressant Surmontil (trimipramine) increases the risk of diabetes 146%—or 2.5-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

The dose was 50 mg per day or above that increased the risk.

The antidepressant Luvox (fluvoxamine) increases the risk of diabetes 391%—or 4.9-fold—according to an analysis by researchers from Charité University Medical Center in Berlin, Germany.

They forgot to give the cutoff dose at which the risk increased.

Diabetics who were randomly assigned to an Intensive Lifestyle Intervention lost an average of 8.6 percent of body weight after one year compared to 0.7 percent for those randomly assigned to Diabetes Support and Education according to a recent study.

Shortened sleep reduces leptin, a hormone which reduces appetite, and increases ghrelin, a hormone which increases appetite notes a review paper on the association of lack of sleep to obesity and diabetes.

Diabetic patients using subcutaneous injections of Symlin (pramlintide), as well as diet, exercise and lifestyle changes, lost an average of 7.9 pounds in six months versus 4.6 pounds in those given injections of a placebo, a increase of 3.3 lbs—a small increase in weight loss—according to a new study from the makers of Symlin (pramlintide).

Diabetic patients who took phentermine in addition to giving themselves subcutaneous injections of Symlin (pramlintide), as well as diet, exercise and lifestyle changes, lost an average of 23.9 lbs in six months versus 7.9 lbs with Symlin (pramlintide) injections alone versus 4.6 lbs in those given injections of a placebo, a difference of 19.3 lbs according to a new study from the makers of Symlin (pramlintide).

Diabetic patients who took Meridia (sibutramine) in addition to giving themselves subcutaneous injections of Symlin (pramlintide), as well as diet, exercise and lifestyle changes, lost an average of 23.9 lbs in six months versus 4.6 lbs in those given injections of a placebo, a difference of 19.3 lbs according to a new study from the makers of Symlin (pramlintide).

A 10-pound weight loss reduces the risk of type II diabetes by approximately 30 percent according to a two-year study of 154 obese patients who had at least one parent with diabetes.